Bowel/fecal incontinence refers to a patient’s inability to control bowel movements, which results in involuntary loss of solid or liquid stool. It is caused due to diarrhea, constipation, weaker muscle tone (that controls the opening of the anus), and chronic medical conditions (such as diabetes, multiple sclerosis, and nerve damage). The clinical devices used to manage bowel activity are called bowel management systems.
Expected Surge in Revenue:
The global bowel management systems market is projected to reach USD 2.07 billion by 2023, at a CAGR of 3.5%.
Major Growth Boosters:
Some of the major factors driving the growth of this market are: expanding target patient population, rapidly growing geriatric population, availability of technologically advanced bowel management products, and favorable reimbursement scenario in developed countries.
Download PDF Brochure@
Restraint: Patient preference for non-invasive clinical management of FI
Currently, FI can be managed invasively (surgically) or non-invasively. Standard modes of surgical treatment include the injection of biomaterials into the anal canal, radiofrequency treatment of the anal canal, surgical repair of anal muscle injuries, sacral nerve stimulation, artificial bowel sphincter, muscle transposition to reinforce the anal sphincter, and the creation of a stoma. These often require long-term patient rehabilitation and maybe highly inconvenient and even severely painful.
Critical questions the report answers:
# Where will all these developments take the bowel management systems market in the long term?
# What are the upcoming trends for the bowel management systems market? Which segment in the bowel management market provides the most opportunity for growth?
# Who are the leading vendors operating in the market? What are the opportunities for new market entrants in the bowel management market?
In 2018, Europe accounted for the largest share of the bowel management systems market
Geographically, the bowel management systems market is segmented into North America, Europe, Asia Pacific, and the Rest of the World. Europe accounted for the largest share of the market in 2018. The large share can be attributed to the significant disease (colorectal/bladder cancer & IBD) burden, favorable reimbursement scenario, and the increase in its geriatric population.
# In 2018, Coloplast acquired IncoCare, a provider of continence products. This acquisition helped Coloplast expand its presence in Germany.
# In 2018, Axonics received marketing approval for its Axonics Sacral Neuromodulation System in Australia.
# In 2018, Coloplast expanded its product portfolio by introducing a new product, SenSura Mio Concave, into its SenSura Mio product line.
# In 2016, ConvaTec entered into an agreement with Vizient, Inc. According to this agreement, members of Vizient get access to ConvaTec’s stoma care, bowel management, and patient skincare products.
# In 2016, A German court affirmed ConvaTec’s patent protection on Flexi-Seal Fecal Management System and ordered the competitor to cease from placing its product (infringing patent) in the market, as well as to recall its product already sent to market and to compensate ConvaTec.
Request Sample Pages@
Some of the major players operating in the bowel management systems market are Coloplast (Denmark), Medtronic (Ireland), 3M (US), B. Braun (Germany), C.R. Bard (US), Consure Medical (India), Cogentix Medical (US), Aquaflush Medical Limited (UK), Axonics Modulation Technologies (US), ConvaTec (UK), Hollister (US), MBH-International A/S (Denmark), Mederi Therapeutics Inc. (US), Welland Medical limited (UK), and Wellspect HealthCare (Sweden).
An analysis of market developments between 2015 and 2018 revealed that growth strategies such as product launches and approvals, agreements, expansions, and acquisitions were adopted by market players to strengthen their product portfolios and maintain a competitive position in the bowel management systems market. Among these, product launches and approvals were the most widely adopted growth strategies